Symptomtext
Immune thrombocytopenia purpuria; bleeding of gums, nose, skin pricks; bleeding of gums, nose, skin pricks; bleeding of gums, nose, skin pricks; platelet count of 1000; This is a spontaneous report from a contactable nurse reported for herself. This 69-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Lot number ELU266), via an unspecified route of administration at single dose in left arm on 20Feb2021 12:45 for COVID-19 immunisation. Medical history included allergies to medications penicillins, ceclor, statins, environmental; diabetes; hypertension; asthma; gastrooesophageal reflux disease. The vaccine was administered at Health Clinic. Concomitant medications included rabeprazole, clonazepam, montelukast, venlafaxine hydrochloride. On 22Feb2021, the patient experienced immune thrombocytopenia purpuria, bleeding of gums, nose, skin pricks, platelet count of 1000. Therapeutic measures were taken as a result of the events included steroids, IVGM, platelets, PRBC, iron, antibiotics. The outcome of the events was recovering. The patient was hospitalized and condition was life threatening. The patient underwent lab tests and procedures which included platelet count: 1000 on 22Feb2021, SARS-CoV-2 test: negative on 07Mar2021.; Sender's Comments: A contributory role of the vaccine BNT162B2 to reported events cannot be excluded based on plausible temporal relationship and lack of alternate explanation at this time. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.